SDS Optic S.A. of Lublin at MEDICA 2019 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

SDS Optic S.A.

Konstantynow 1F, 20-708 Lublin
Poland

This company is co-exhibitor of
World Expo International Sp. z o.o.

Hall map

MEDICA 2019 hall map (Hall 16): stand F42

Fairground map

MEDICA 2019 fairground map: Hall 16

Contact

Mateusz Sagan

Our range of products

Product categories

  • 01  Electromedical Equipment / Medical Technology
  • 01.01  Diagnostics
  • 01.01.13  Other diagnostic equipment

Other diagnostic equipment

  • 03  Diagnostic Tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

Our products

Product category: Diagnostic tests for cancer

Medical devices

inPROBE – disruptive platform technology with global potential to challenge the paradigm of targeted biology diagnostics and real-time targeted drugs delivery monitoring
Nowadays millions of people die each year from cancer. It’s a medical professionals to save lives of patients worldwide.At the same time the future of cancer therapies is here, several targeted or gene therapies are gaining trust, but their efficiency strictly depends on proper and real time targeted tumor biology diagnostics, which doeas not exist today. That’s why we’ve einvented and developed inPROBE, a platform technology which links targeted therapies with targeted diagnostics.Our technology will reduce diagnosis time, will increase precision and effects of innovative cancer treatments. It can be used both in cancer diagnostics and therapies monitoring in real time and in natural state, thus giving medical professionals a fast and efficient tools previously unavailable.

More Less

Product category: Diagnostic tests for cancer

Biotech r&d

SDS Optic, based in Lublin, Poland, is a cutting-edge biotech company specializing in connecting vast medical knowledge with technical skills to create medical devices that can revolutionize healthcare worldwide.

Our strategy is to discover, develop, produce and commercialize on global scale unique diagnostics and monitoring tools working in real-time and in natural state, which support and save lives.

We concentrate on helping the healthcare with faster, less painful diagnostics and supporting targeted, effective treatment procedures. We develop and create different diagnostics & monitoring solutions, incl. the ones used in cancer diagnostics and cancer treatment. Our team consists of renown experts in biology, optoelectronics, physics, medicine, advanced technologies, chemistry and related sciences.

SDS Optic is innovative integrated multidisciplinary biotechnology R&D partner for the pharmaceutical and biotechnology industries with office in Lublin, Poland and research associates both in Poland and in the United States.

The company offers targeted diagnostics discovery support at every stage of the early discovery phase up to the preclinical research phase.
Currently SDS Optic employs over 10 scientists, majority with PhD degree and extensive experience in several areas of life sciences, offering the following types of projects:

  • Contract Chemistry services
  • Molecular Biology services
  • Targeted innovative multidisciplinary in vivo diagnostics & monitoring solutions development
  • Comparative studies of biosimilar products
  • Integrated multiple key-steps pre-clinical discovery projects
  • Early stage in vivo & in vitro diagnostic technologies scale-up and commercialization

More Less

Product category: Other diagnostic equipment

inPROBE Smart Cancer Diagnostics

inPROBE, invented and developed by SDS Optic, is cancer diagnosis device designed to reduce time of medical diagnosis, increase precision and effects of advanced cancer treatments and most importantly – help medical professionals to save lives of millions of patients worldwide. It can be used both in cancer diagnostics and therapies monitoring in real-time and natural state (in vivo), thus giving the medical professionals tools and methods previously unavailable.

New disruptive inPROBE technology which has a key value potential in 4 below major areas:
- new view on cancer tumor markers diagnosis (real-time, in vivo, numerical results)
- targeted diagnostics device which could help to identify cancer patients responding to dedicated cancer targeted therapies (f.e. Trastuzumab)
- targeted cancer therapies monitoring (real-time, in vivo tumor drug delivery notification and numerical assessments)
- supporting finding new molecules for cancer treatment and supporting new drugs development (by shortening pre-clinical research pathway time & expenses).
inPROBE, invented by SDS Optic, is a disruptive technology merging fiber-optic elements with innovative molecular biology, chemistry and engineering components.
inPROBE in essence is putting the IHC/FISH (histopathology) diagnostic tests at the tip of a 6-micron optic fiber microprobe with single-cell resolution giving numerical tumor markers in vivo examination results in real time, with HER2 cancer markers diagnosis as first developed application and a wide range of scale-up opportunities.

More Less

About us

Company details

Who we are
SDS Optic develops and creates innovative solutions on the borderline of biochemistry, engineering and fibre optic technologies, that can be used in cancer diagnosis and treatment. Company designed a revolutionary opto-biological methodology that allows for instant cellular processes studies including in-vivo cancer diagnosis with single-cell resolution. inPROBE detects presence and measures concentration levels of the HER+ cancer cells in breast tumours. It is a breakthrough device that carries the potential to address the challenges of SoA cancer markers diagnosis and biopsies. In essence, it is a laboratory test at the tip of a probe, but with greater accuracy, efficacy and quantitative results. SDS-OmiProbe may also be used as a companion diagnostic tool for targeted therapy and targeted therapy drugs.Additionally company was granted €3.985.000 from the SME Instrument (Horizon 2020) programme to develop a revolutionary optical device OmiProbe for safe, fast and non-destructive cancer diagnosis.

New Technology
 Our technology is a breakthrough. We create a tool for direct measurement of the HER2 marker. The use of a microsonde will save the patient pain and stress associated with biopsy and waiting for the result – says Marcin Staniszewski, President of the Board of SDS Optic and the originator of the microscope, a graduate of the University of Akron and a collaborator of NASA Laboratory.

Mission
Our vision is to make widespread use of our technology to diagnose breast cancer. According to WHO analyses, a fast and effective cancer diagnosis can lead to a reduction in mortality of up to 30%. The problem affects hundreds of thousands of women around the world, who thanks to our technology will receive reliable and fast diagnosis and better chances for curing – adds Magdalena Staniszewska, PhD, Chief Science Officer of SDS Optic and the originator of the microscope, for many years associated with Harvard Medical School in Boston.

Research and innovations
The research and development centre opened on 19 April will allow intensifying the work of SDS Optic on a globally unique technology of in vivo diagnostics, directly in the patient’s body. The laboratory is divided into three areas, each of which will have a qualified team of biologists, chemists, biomedical engineers and physicists. The company is in the process of developing its interdisciplinary team, and scientists who join the group often return from abroad, including the UK and Italy.

Thanks to the support we received from our Investor, we managed to purchase professional and modern laboratory equipment, which includes, among others a chromatograph and ChemicalDoc system for gel imaging and analysis from Bio-Rad, an advanced spectrophotometer, Nikon’s flagship model of fluorescence microscope, and a range of basic equipment and accessories for a modern laboratory, including a professional system for low temperature storage of cells and tissues, incubators, autoclaves, fume cupboards, centrifuges and shakers. Thanks to such professional equipment of our laboratory we will be able to carry out further stages of work and develop our crucial technology on our own. A laboratory, with such equipment and opportunities concerning development, including business from the first days of its operation, is a certain asset for our shareholders – describes Mateusz Sagan, Director of Development and Member of the Supervisory Board of SDS Optic.

Revolution in world oncology diagnostic
The SDS Optic team is working on a breakthrough technology based on rapid detection of the test substance in the body, including cancer markers, with particular accuracy, the use of laser beams and the use of innovative components. At the end of the process, the reading is interpreted on the detector using an appropriate conversion algorithm, which gives the level of the tested compound (e.g. HER2 cancer marker) in a numerical form. Due to the high sensitivity of detection, it will not be necessary to measure the markers inside the tumour tissue itself, but in its vicinity.

Thanks to the use of a thin microsound, the device is to perform accurate, very fast and less painful measurement of tumour markers. Currently, SDS Optic focuses on breast cancer, with particular emphasis on the measurement of the HER2 and CCL markers.5 Such diagnosis will allow physicians to start a therapy suitable for the patient much faster, which in turn will translate into the effectiveness of the treatment process.
 
European grants winner
The development of innovative technology for the production of laser microsomes is possible thanks to the significant support of SDS Optic from public funds. The National Centre for Research and Development co-financed the project under the STRATEGMED and PatentPlus programmes. INNOventure also invested PLN 3 million in the development of SDS Optic, a fund of the Kraków Technology Park and private investors established as part of the initiative of NCBiR – BRIdge Alfa.

Programmes implemented by the National Centre for Research and Development are an excellent example of cooperation between state institutions, scientists and entrepreneurs. In the case of BRIdge Alfa, thanks to the use of private and public capital, as well as the knowledge of professional management teams, we can search for and support projects which today are carried out in intimate academic environments, and tomorrow have a chance to become Polish unicorns – says Prof. Aleksander Nawrat, Deputy Director of the National Centre for Research and Development.

SDS Optic is also one of the largest beneficiaries of the SME Facility under the “Horizon 2020” programme of the European Commission and a member of the “Lublin Medicine Cluster”.

 

More Less

Company data

Sales volume

< 1 Mio US $

Number of employees

20-49

Foundation

2013

Area of business
  • Electromedical equipment / Medical Technology
  • Diagnostics